Winton Group’s Aldeyra Therapeutics ALDX Stock Holding History

Winton Group’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,048	Closed	-$118K	–	1117
2019 Q1	$118K	Buy	+13,048	New	+$111K	﹤0.01%	1020

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Winton Group's ALDX Position: Q2 2019 in Review

Winton Group sold out of Aldeyra Therapeutics (ALDX) in Q2 2019, closing a stake of 13,048 shares — an estimated $118K sold.

Winton Group first reported a position in ALDX in Q1 2019 and held it in 1 quarter. The position peaked at $118K in Q1 2019. 76 funds tracked by Wall St. Rank hold ALDX as of Q2 2019.

Winton Group reported no remaining Aldeyra Therapeutics position as of Q2 2019 after selling out during the quarter.
Winton Group sold 13,048 Aldeyra Therapeutics shares in Q2 2019, an estimated $118K.
Winton Group first reported a position in Aldeyra Therapeutics in Q1 2019 and held it in 1 quarter.
Winton Group's Aldeyra Therapeutics position peaked at $118K in Q1 2019.
76 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2019.

Based on Winton Group's 13F filing for Q2 2019, filed 8 Jul 2019.